Polymeric treatment compositions

Patent metadata

Field	Value
Publication number	US-2018200288-A1
Application number	US-201815924028-A
Country	US
Kind code	A1
Filing date	Mar 16, 2018
Priority date	Jun 14, 2012
Publication date	Jul 19, 2018
Grant date	—

Abstract

Compositions are described comprising a polymer; a non-physiological pH solution; and a visualization agent; wherein the polymer is soluble in the non-physiological pH solution and insoluble at a physiological pH. Methods of forming the solutions and polymers are disclosed as well as methods of therapeutic use.

First claim

We claim:

1 . A composition comprising:
a biocompatible polymer comprising at least one monomer wherein at least one monomer includes an ionizable moiety; a solution with a non-physiological pH; and a visualization agent; wherein the biocompatible polymer is soluble in the solution and insoluble at a physiological pH at a treatment site.

2 . The composition of claim 1 , wherein the visualization agent is a particulate.

3 . The composition of claim 1 , wherein the visualization agent has a concentration of about 5% to about 65%.

4 . The composition of claim 1 , wherein the visualization agent is an iodinated compound, barium sulfate, tantalum, superparamagnetic iron oxide, gadolinium molecules or a combination thereof.

5 . The composition of claim 1 , wherein the polymer is a reaction product of two different monomers.

6 . The composition of claim 1 , wherein the polymer is a reaction product of three different monomers.

7 . The composition of claim 1 , wherein the non-physiological pH solution is aqueous.

8 . The composition of claim 1 , wherein the non-physiological pH solution is water.

9 . The composition of claim 1 , wherein the non-physiological pH solution has a pH of less than about 6.

10 . The composition of claim 1 , wherein the non-physiological pH solution has a pH of greater than about 8.

11 . The composition of claim 1 , wherein the polymer has a concentration of about 1% w/w to about 35% w/w.

12 . A composition comprising:
a first aqueous solution at non-physiological pH; a biocompatible polymer comprising at least one monomer wherein the polymer has a concentration of from about 1% to 35% w/w, that is soluble in the first aqueous solution at non-physiological pH and insoluble in a second aqueous solution at physiological pH; and a particulate visualization agent at a concentration of from about 5% w/w to about 65% w/w.

13 . The composition of claim 12 , wherein the visualization agent is a particulate.

14 . The composition of claim 12 , wherein the visualization agent has a concentration of about 20% to about 60%.

15 . The composition of claim 12 , wherein the visualization agent is an iodinated compound, barium sulfate, tantalum, superparamagnetic iron oxide, gadolinium molecules or a combination thereof.

16 . The composition of claim 12 , wherein the polymer is a reaction product of two different monomers.

17 . The composition of claim 12 , wherein the polymer is a reaction product of three different monomers.

18 . The composition of claim 12 , wherein the non-physiological pH solution is water.

19 . The composition of claim 12 , wherein the non-physiological pH solution has a pH of less than about 6.

20 . The composition of claim 12 , wherein the non-physiological pH solution has a pH of greater than about 8.

Assignees

• Microvention Inc

Inventors

• Cruise Gregory M
• Constant Michael J
• Garretson Joshua

Classifications

• A61P9/00

  Drugs for disorders of the cardiovascular system · CPC title

• A61K31/78

  of acrylic acid or derivatives thereof · CPC title

• A61K47/30

  Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates · CPC title

• A61L2430/36

  for embolization or occlusion, e.g. vaso-occlusive compositions or devices · CPC title

• A61K31/785 Primary

  Polymers containing nitrogen · CPC title